Test Price
2,800 AED✅ Home Collection Available
BMP1 Gene Osteogenesis Imperfecta Type 13 Genetic Test in UAE
Executive Summary & Core Metrics
2,800 AED · DHA Clinical Genetic Guidelines
- 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Interpretation by certified molecular geneticists.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) panel comprehensively screens the BMP1 gene for pathogenic variants associated with Osteogenesis Imperfecta Type 13, a severe connective tissue disorder distinguished by recurrent fractures and bone fragility. The assay provides definitive molecular classification to differentiate OI Type 13 from other collagenopathies and genetic skeletal disorders, enabling precise prognosis and family planning.
| Feature | DNA Labs UAE Genomic Test | Closest Alternative (Single Gene Sanger) |
|---|---|---|
| Precision | 99.9% Analytical Sensitivity via NGS with CNV & Intronic Splice Site Analysis | Moderate; restricted to targeted exons only |
| Method | Next-Generation Sequencing (NGS) | Bidirectional Sanger Sequencing |
| Speed (TAT) | 3 to 4 Weeks with Interim Clinical Reports | 6 to 8 Weeks |
Physician Insight & Safety Protocols
"Genetic diagnosis for Osteogenesis Imperfecta Type 13 requires careful clinical correlation and integration with the patient's fracture history and multisystem involvement. This comprehensive NGS assay provides definitive molecular classification that differentiates OI Type 13 from other connective tissue disorders, enabling precise prognostic counseling and informed family planning decisions."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Therapeutic Medication Advisory
⚠ Critical Medication Advisory
Do not discontinue any prescribed bisphosphonate therapy, calcium, or vitamin D supplementation without explicit consultation with your managing physician. Genetic test results do not replace acute clinical fracture management or ongoing metabolic bone treatment.
Exclusion Criteria & Emergency Red Flags
- Specimen Rejection: Clotted blood samples, non-sterile FTA cards, or samples without dual patient-physician identifier labeling.
- Administrative Lock: Mandatory notarized guardian consent for minors; unaccompanied minors cannot undergo phlebotomy per UAE Federal Law.
- URGENT: Seek immediate emergency care for sudden vision loss, acute hearing loss, or basilar skull fracture symptoms independent of genetic testing timelines.
Patient FAQ & Clinical Guidance
1. What specific mutations does the BMP1 NGS test identify, and how does it compare to standard bone density scans?
This comprehensive NGS assay identifies single nucleotide variants, small insertions/deletions, and copy number changes throughout the entire BMP1 coding region, providing molecular confirmation that standard DEXA bone densitometry cannot offer for differentiating genetic fragility types.
2. Why is a 3 to 4 week turnaround required for BMP1 analysis when other blood tests are faster?
The extended TAT accommodates the complex bioinformatics pipeline required for high-fidelity NGS, including library preparation, iterative alignment against the GRCh38 reference genome, and multi-disciplinary variant classification by molecular pathologists before final sign-out.
3. Can I use an FTA card collected at home for this specific NGS to avoid a clinic visit?
Yes, a single drop of blood properly applied to a sterile DNA FTA card by our DHA-licensed VIP mobile phlebotomist during the home visit is a fully validated sample type, ensuring DNA stability during ambient temperature cold-chain transport to the sequencing facility.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, access-restricted, and processed exclusively within UAE jurisdiction with explicit patient consent.
Clinical & Logistical Metadata
| Test Name | BMP1 Gene Osteogenesis Imperfecta Type 13 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Sterile DNA FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV & Intronic Splice Site Analysis |
| ICD-10-CM Code | Q78.0 |
| LOINC Code | 93025-1 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians